Announced details
DDAIF has been adopted by multiple major pharmaceutical companies. The specific number of companies and cumulative number of deployments are Not disclosed.
FRONTEO conducts joint research or industry-academia collaboration with the Institute of Science Tokyo and the University of Oklahoma, has a strategic partnership agreement with Q Partners LLC, discusses out-licensing and the adoption of DDAIF with pharmaceutical companies, and engages in joint drug discovery and research and development collaboration with biotech ventures.
Institute of Science Tokyo, the University of Oklahoma in the U.S., Q Partners LLC, multiple pharmaceutical companies, and biotech ventures are involved. Details such as the location, representatives, and capital stock of each counterparty are limited in this document.
The technologies related to DDAIF have secured a total of 21 patent rights in Japan, South Korea, the U.S., and Europe. Expiration dates and individual patent numbers are Not disclosed.
Several dozen researchers and AI engineers
FRONTEO states that it plans to expand or secure discontinuous revenue opportunities, but the specific impact on sales and profit is Not disclosed.
The company does not address Contract Value / Offering price.
FRONTEO's previous press releases and the URL for its list of DDAIF initiatives.
| Item | Details |
|---|---|
| Names of Products / Services Covered | KIBIT AI Biology Lab, Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Institute of Science Tokyo, University of Oklahoma, U.S., Q Partners LLC, Multiple pharmaceutical companies, Biotech ventures |
| Counterparty overview | Institute of Science Tokyo, the University of Oklahoma in the U.S., Q Partners LLC, multiple pharmaceutical companies, and biotech ventures are involved. Details such as the location, representatives, and capital stock of each counterparty are limited in this document. |
| Relationship with the Company | FRONTEO conducts joint research or industry-academia collaboration with the Institute of Science Tokyo and the University of Oklahoma, has a strategic partnership agreement with Q Partners LLC, discusses out-licensing and the adoption of DDAIF with pharmaceutical companies, and engages in joint drug discovery and research and development collaboration with biotech ventures. |
| Contract Date | The strategic partnership agreement with Q Partners LLC was signed on 25 June 2025. The dates of other agreements and discussions are Not disclosed. |
| Launch date | KIBIT AI Biology Lab opened on 13 May 2026. The DDAIF update and the new operating structure began with the launch of this center. |
| Applicable area | AI drug discovery, Target molecule discovery and hypothesis generation, Rare diseases, Cancer, Pancreatic cancer, Pharmaceutical Research and Development, In the future, materials, food, and cosmetics |
| Registration number and expiry date | The technologies related to DDAIF have secured a total of 21 patent rights in Japan, South Korea, the U.S., and Europe. Expiration dates and individual patent numbers are Not disclosed. |
| Location scale | Several dozen researchers and AI engineers |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies. The specific number of companies and cumulative number of deployments are Not disclosed. |
| Impact on Business Performance | FRONTEO states that it plans to expand or secure discontinuous revenue opportunities, but the specific impact on sales and profit is Not disclosed. |
| Source | FRONTEO's previous press releases and the URL for its list of DDAIF initiatives. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The center was established as a core hub for the AI drug discovery business and joint research with academia, creating a structure that covers the upstream end of the drug discovery value chain. FRONTEO explains that it aims to expand its out-licensing pipeline for pharmaceutical companies, enhance research and development, improve the probability of success in drug discovery, and expand revenue opportunities.